TuHURA Biosciences, Inc. HURA

NAS: HURA | ISIN: US8989201038   2/04/2026
1,410 USD (-12,96%)
(-12,96%)   2/04/2026

1 april 2026 · TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update · Persbericht

23 maart 2026 · Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers · Persbericht

27 februari 2026 · TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

24 februari 2026 · TuHURA Biosciences Announces Participation in Upcoming Investor Conferences · Persbericht

17 februari 2026 · TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers · Persbericht

12 februari 2026 · TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference · Persbericht

2 februari 2026 · TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma · Persbericht

15 december 2025 · TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone · Persbericht

11 december 2025 · TuHURA Biosciences Provides Corporate Update Following Recent Financing · Persbericht

9 december 2025 · TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering · Persbericht

8 december 2025 · TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition · Persbericht

14 november 2025 · TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update · Persbericht

3 november 2025 · TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition · Persbericht

20 augustus 2025 · TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference · Persbericht

14 augustus 2025 · TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update · Persbericht

1 juli 2025 · TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes · Persbericht

30 juni 2025 · TuHURA Biosciences Completes Acquisition of Kineta · Persbericht

24 juni 2025 · TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma · Persbericht

23 juni 2025 · TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals · Persbericht

10 juni 2025 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders · Persbericht

Mijn selecties